Clinical Trials Logo

Ophthalmopathy clinical trials

View clinical trials related to Ophthalmopathy.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05494242 Completed - Ophthalmopathy Clinical Trials

Single Superior ILM/ERM Flap for the FTMH.

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

In this study, the investigators will make the only upper flap either from the internal limiting membrane or from the epiretinal membrane to cover the full thickness macular hole.

NCT ID: NCT04982484 Completed - Clinical trials for Wet Macular Degeneration

Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment

PAMER
Start date: September 1, 2010
Phase:
Study type: Observational

AMD (age-related macular degeneration), is the leading cause of blindness in individuals over the age of 55. There is no cure for wet-AMD but anti-VEGF treatments significantly minimize the vision loss over time. To study the correlation between anti-VEGF injection bevacizumab (Lucentis), visual acuity, macular thickness and last but not least reading speed in wet-AMD patients. The study was conducted on 50 eyes of 50 wet-AMD patients. Subjects were monthly treated with an intra-vitreal Lucentis injection for 3 months; further injections were given when a loss of 5 or more letters of visual acuity was observed and/or when the retinal thickness in the affected macular area increased by 100 µm. In addition to a full ophthalmological examination reading speed was investigated via the Radner reading chart before and 3 months after treatment. The collected data was analyzed using paired t-tests.

NCT ID: NCT04917562 Completed - Myopia Clinical Trials

Refractive Transepithelial Photo-keratectomy (T-PKR) in High Myopia

TEPEHERKAHM
Start date: January 1, 2018
Phase:
Study type: Observational

The aim of this study is to evaluate the anatomical and refractive parameters following a single-step transepithelial photo-refractive keratectomy (T-PRK) without the addition of mitomycin-C for the treatment of high myopia of 6 diopters or more.

NCT ID: NCT04771039 Completed - Clinical trials for Inflammatory Bowel Diseases

Ocular Manifestations of Inflammatory Bowel Disease

Start date: January 1, 2013
Phase:
Study type: Observational

Ocular damage is found in the 3rd rank of extra intestinal manifestations (MEI) Potentially serious functional complications (see uveitis and risk of blindness) requiring rapid management Rare uveitis in the literature (0.5% -3%), study on a large sample to assess their prevalence in patients with IBD at the Nancy CHRU and describe all the ocular manifestations that can be found.

NCT ID: NCT04683055 Completed - Glaucoma Clinical Trials

Phaco-Trabeculotomy Vs Phaco-Trabeculectomy

PDT vs PT
Start date: October 28, 2020
Phase: N/A
Study type: Interventional

A prospective, randomized comparative study on adult patients with synechial angle closure glaucoma.

NCT ID: NCT04387292 Completed - COVID19 Clinical Trials

Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

SOCOVID
Start date: September 7, 2020
Phase: N/A
Study type: Interventional

Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation. COVID-19 itself, has several components: - An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular - A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary "hyper" inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases. - A thromboembolic action

NCT ID: NCT03855462 Completed - Ophthalmopathy Clinical Trials

Evaluating Medium-chain Triglycerides as a Temporary Intraocular Tamponading Agent for Retinal Detachment

MCT
Start date: December 17, 2018
Phase: N/A
Study type: Interventional

Background : Surgery is needed in order to flatten and position a detached retina onto the choroid, to allow sealing of the tears and to prevent or reverse vision loss. In case of complex retinal detachment vitrectomies followed by ocular endotamponade - non-solid implants used in ophthalmology - is the most common treatment. Despite several options used by surgeons were not entirely satisfactory, no innovation were marketed in the ocular endotamponade field since decades. Purpose : Regarding comparative physico-chemical properties of medium-chain triglycerides (MCT) with current tamponading agents (silicone oil or gases), it will be proposed to evaluate the MCT as an ocular endotamponade product.

NCT ID: NCT03766737 Completed - Clinical trials for Artificial Intelligence

Validation of the Utility of an Intelligent Visual Acuity Diagnostic System for Children

Start date: May 20, 2018
Phase: N/A
Study type: Interventional

Visual development during early childhood is a vital process. Examining the visual acuity of children is essential for the early detection of visual abnormality, but performing such an assessment in children is challenging. Here, the investigators developed a human-in-the-loop artificial intelligence (AI) paradigm that combines traditional vision examination and AI with integrated software and hardware, thus making the vision examination easy to perform. The investigator also establish a entity intelligent visual acuity diagnostic system based on the paradigm, and conduct clinical trial to validate if the diagnostic system can offsetting the shortcomings of human doctors.

NCT ID: NCT03499145 Completed - Clinical trials for Artificial Intelligence

Validation of the Utility of Ophthalmology Intelligent Diagnostic System

Start date: April 1, 2018
Phase:
Study type: Observational

The prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. Application scenarios of the current medical algorithms are too simple to be generally applied to real-world complex clinical settings. Here, the investigators use "deep learning" and "visionome technique", an novel annotation method for artificial intelligence in medical, to create an automatic detection and classification system for four key clinical scenarios: 1) mass screening, 2) comprehensive clinical triage, 3) hyperfine diagnostic assessment, and 4) multi-path treatment planning. The investigator also establish a telemedicine system and conduct clinical trial and website-based study to validate its versatility.

NCT ID: NCT03492242 Completed - Cancer Clinical Trials

Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction

CHIMeRA
Start date: February 1, 2018
Phase:
Study type: Observational

Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin. This study investigates reports of drug induced irAEs with treatment including anti-PD1, Anti-PDL-1, and Anti-CTLA4 classes using the World Health Organization (WHO) database VigiBase and the french database Base Nationale de PharmacoVigilance (BNPV).